Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Richard Segiel, Jr. Joins Almac as Vice President of US Business Development

Published: Wednesday, October 30, 2013
Last Updated: Wednesday, October 30, 2013
Bookmark and Share
Richard will focus on developing new business, maintaining existing business, and developing partnerships.

Almac’s Clinical Services Business Unit has announced that Richard Segiel, Jr. has joined the company as Vice President of Business Development for the United States. He brings with him 23 successful years of experience in the contract pharmaceutical development sector. In his new role, he will focus on developing new business, maintaining existing business, and developing partnerships.

Prior to joining Almac, Richard held a number of Business Development and Operational positions at Intertek Pharmaceutical Services, MDS Tricon, Celsis Analytical Services, and Pharmakon Research International.

“Richard brings a compelling mix of business development, operational, and financial experience that will further strengthen Almac's leadership team. This skill set is key to delivering on our core objective of enhancing our US client relationships, further developing our commitment to customer service, and helping achieve true strategic partnerships,” said Martin Lamb, Global VP of Business Development.

Most recently, Richard served as Business Development Director of Intertek Pharmaceutical Services where he had direct responsibility for all Business Development and Sales initiatives for the company’s Chemical and Pharmaceutical Division NA.

As Vice President, Business Development at Celsis Analytical Services, Richard assembled the sales and client services divisions, which achieved record sales performance for six consecutive years under his supervision.

Additionally, Richard implemented many sales infrastructure programs including the organization’s first CRM system, new KPI metrics, as well as successful sales compensation plans.

“We are very pleased to have Richard on our growing Business Development team. Richard’s experience in the contract pharmaceutical development sector coupled with his proven ability to develop, build, and manage a world-class sales force will make him a vital asset to our team,” says Robert Dunlop, President of Almac’s Clinical Services Business Unit. “Our goal was to find a proven leader who could help us grow our business in the US, and Richard is the perfect fit.”

Richard holds a bachelor’s degree in Chemistry and Business from the University of Scranton and an MBA in Marketing and Finance. Richard lives in Gouldsboro, Pennsylvania with his wife Kimarie and their two children.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Almac Wins Laboratory Team of the Year at The Irish Laboratory Awards 2013
The awards held to recognize the success and achievements of Ireland’s internationally renowned scientists.
Thursday, December 12, 2013
Almac Secures New Metagenomics and Enzyme Discovery Programme with UCL
The BBRSC Programme combines Chemistry and Biochemical Engineering at UCL with Almac’s Biocatalysis Group.
Wednesday, May 15, 2013
Todd Kole Appointed to Almac’s Clinical Technologies Executive Team
Todd will oversee clinical project management and drug supply services globally.
Tuesday, August 30, 2011
Scientific News
Spero Therapeutics Announces $30 Million Series B Preferred Financing
Company has announced financing of $30 million to support development of novel therapies to treat gram-negative bacterial infections.
Keeping Tumor Growth at Bay
Engineers at Washington University in St. Louis found a way to keep a cancerous tumor from growing by using nanoparticles of the main ingredient in common antacid tablets.
Future of Medicine Could be Found in a Tiny Crystal Ball
A Drexel University materials scientist has discovered a way to grow a crystal ball in a lab. Not the kind that soothsayers use to predict the future, but a microscopic version that could be used to encapsulate medication in a way that would allow it to deliver its curative payload more effectively inside the body.
Improving Delivery of Poorly Soluble Drugs Using Nanoparticles
A technology that could forever change the delivery of drugs is undergoing evaluation by the Technology Evaluation Consortium™ (TEC). Developed by researchers at Northeastern University, the technology is capable of creating nanoparticle structures that could deliver drugs into the bloodstream orally – despite the fact that they are normally poorly soluble.
Faster Drug Discovery?
Startup develops more cost-effective test for assessing how cells respond to chemicals.
New Mechanism of Antitumor Action Identified
A team of UAB researchers and collaborators from the Catalan biotech company Ability Pharmaceuticals (UAB Research Park), have described a new mechanism of anti-tumour action, identified during the study and development of the new drug ABTL0812.
Nanoparticles Deliver Tumor Suppressors to Damaged Livers
UT Southwestern Medical Center chemists have successfully used synthetic nanoparticles to deliver tumor-suppressing therapies to diseased livers with cancer, an important hurdle scientists have been struggling to conquer.
Experimental Combination Surprises with Anti-HIV Effectiveness
A compound developed to protect the nervous system from HIV surprised researchers by augmenting the effectiveness of an investigational antiretroviral drug beyond anything expected.
A New Type of Anticancer Agent
Success in the development of a ?-tubulin specific inhibitor.
Nanoparticles Proven Effective Against Antibiotic-Resistant “Superbugs”
In the ever-escalating evolutionary battle with drug-resistant bacteria, humans may soon have a leg up thanks to adaptive, light-activated nanotherapy developed by researchers at the University of Colorado Boulder.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!